These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17067637)

  • 1. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
    Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
    Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
    Miller DK; Rodvelt KR; Constales C; Putnam WC
    Life Sci; 2007 Jun; 81(1):63-71. PubMed ID: 17532007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
    Gifford AN; Ashby CR
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR; Koek W
    Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
    Kathmann M; Bauer U; Schlicker E; Göthert M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large receptor reserve for cannabinoid actions in the central nervous system.
    Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
    J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.
    Kathmann M; Weber B; Schlicker E
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):50-6. PubMed ID: 11191836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.
    Gifford AN; Samiian L; Gatley SJ; Ashby CR
    Eur J Pharmacol; 1997 Apr; 324(2-3):187-92. PubMed ID: 9145770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide.
    Melis MR; Succu S; Mascia MS; Sanna F; Melis T; Castelli MP; Argiolas A
    Neuropharmacology; 2006 Feb; 50(2):219-28. PubMed ID: 16288932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human.
    Martin RS; Luong LA; Welsh NJ; Eglen RM; Martin GR; MacLennan SJ
    Br J Pharmacol; 2000 Apr; 129(8):1707-15. PubMed ID: 10780977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.
    Gifford AN; Tang Y; Gatley SJ; Volkow ND; Lan R; Makriyannis A
    Neurosci Lett; 1997 Nov; 238(1-2):84-6. PubMed ID: 9464661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice.
    Kathmann M; Weber B; Zimmer A; Schlicker E
    Br J Pharmacol; 2001 Mar; 132(6):1169-73. PubMed ID: 11250865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.
    Pozzi O; Misiano P; Clark GD; Visentin L
    Pharmacology; 2003 Nov; 69(3):158-63. PubMed ID: 14512703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat.
    Yüce B; Kemmer M; Qian G; Müller M; Sibaev A; Li Y; Kreis ME; Storr M
    Neurogastroenterol Motil; 2010 Jun; 22(6):672-e205. PubMed ID: 20158615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.
    Schultheiss T; Flau K; Kathmann M; Göthert M; Schlicker E
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Aug; 372(2):139-46. PubMed ID: 16195872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
    Maneuf YP; Crossman AR; Brotchie JM
    Exp Neurol; 1997 Nov; 148(1):265-70. PubMed ID: 9398468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.
    Gamaleddin I; Wertheim C; Zhu AZ; Coen KM; Vemuri K; Makryannis A; Goldberg SR; Le Foll B
    Addict Biol; 2012 Jan; 17(1):47-61. PubMed ID: 21521420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.
    Fattore L; Cossu G; Martellotta CM; Fratta W
    Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
    Zaniewska M; McCreary AC; Przegaliński E; Filip M
    Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.